Sodium–glucose co‐transporter 2 (SGLT2) inhibitors have recently been recommended as a
foundational therapy for patients with heart failure (HF) and reduced ejection fraction …

In the last years, major progress occurred in heart failure (HF) management. Quadruple
therapy is now mandatory for all the patients with HF with reduced ejection fraction. Whilst …

The American College of Cardiology (ACC) has a long history of developing documents (eg,
decision pathways, health policy statements, appropriate use criteria) to provide members …

Episodes of worsening symptoms and signs characterize the clinical course of patients with
chronic heart failure (HF). These events are associated with poorer quality of life, increased …

Background The DAPA‐CKD (Dapagliflozin and Prevention of Adverse Outcomes in
Chronic Kidney Disease) trial (NCT03036150) demonstrated that dapagliflozin reduced the …

Background: Sodium-glucose cotransporter 2 inhibitors have been demonstrated to promote
reverse cardiac remodeling in people with diabetes or heart failure. Although it has been …

Background Because clinical characteristics and prognosis vary by geographic region in
patients with heart failure (HF), the response to treatment may also vary. A previous report …

Empagliflozin (Jardiance®), a sodium-glucose cotransporter 2 inhibitor (SGLT2i) initially
developed to treat type 2 diabetes mellitus (T2DM), has also been approved in the EU and …

Aims Sodium‐glucose cotransporter 2 inhibitors (SGLT2is) have made considerable
progress in the field of heart failure, but their application in arrhythmia remains to be in …

Abstract β-blockers are a heterogeneous class, with individual agents distinguished by
selectivity for β1-vs. β2-and α-adrenoceptors, presence or absence of partial agonist activity …